PaySign, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission for the period ended June 30, 2026, disclosing significant year-over-year increases in revenue, gross profit, and net income.

Key Highlights

  • Total revenues: $56,290,495 for the six months ended June 30, 2026, up from $37,676,502 in the same period of 2025.
  • Net income: $12,195,455 for the first half of 2026, compared to $3,973,861 for the first half of 2025.
  • Q2 2026 net income: $6,756,537, versus $1,387,761 in Q2 2025.
  • Pharma industry revenue: $30,328,585 for the six months ended June 30, 2026, compared to $16,372,559 in the prior-year period.
  • Total assets: $316,989,606 as of June 30, 2026, up from $276,253,203 at December 31, 2025.
  • Total stockholders' equity: $60,156,746 at June 30, 2026, compared to $48,490,171 at December 31, 2025.
  • Shares outstanding: 56,462,156 shares of common stock as of July 30, 2026.

PaySign's Pharma and Plasma Segments Drive First-Half 2026 Results

According to the filing, PaySign, Inc. (Nasdaq: PAYS) recorded total revenues of $28,252,071 for the three months ended June 30, 2026, compared to $19,078,353 in the same quarter of 2025. For the six-month period, total revenues reached $56,290,495 versus $37,676,502 a year earlier. The company reported that pharma industry revenues were $14,649,133 in Q2 2026 versus $7,753,906 in Q2 2025, while plasma industry revenues rose to $13,040,540 from $10,743,924 over the same periods.

The filing shows gross profit for the six months ended June 30, 2026 was $36,115,968, up from $23,445,993 in the comparable prior-year period. Income from operations for the first half of 2026 was $13,679,051, compared to $3,926,673 a year prior. Interest income, net, contributed $1,695,066 to other income for the six-month period, the filing disclosed. Basic earnings per share for the six months were $0.22, compared to $0.07 in the prior-year period, while diluted earnings per share were $0.20 versus $0.07.

On the balance sheet, the company reported cash of $27,372,858 and restricted cash of $149,109,681 as of June 30, 2026. Accounts receivable, net, stood at $103,167,960, up from $72,191,994 at December 31, 2025. Total liabilities were $256,832,860 at quarter end. The company also reported stock-based compensation expense of $2,536,259 for the six months ended June 30, 2026. Common stock issued stood at 57,902,271 shares at June 30, 2026, with 1,459,689 treasury shares held at cost of $5,339,254, according to the filing.

What Was Disclosed

PaySign's 10-Q for the quarter ended June 30, 2026 disclosed material year-over-year increases in revenues, gross profit, and net income, driven primarily by pharma and plasma industry segments, alongside balance sheet growth in total assets and stockholders' equity.